Fibroblast growth factor 19 is released by enterocytes in a feedback mechanism and works through FGFR4 in hepatocytes to reduce bile acid synthesis, making it a novel therapeutic for PBC.28 Fibroblast growth factor-19 analogs are able to mitigate steatosis in the liver by regulating oxidative stress and autophagy.28 Here, FGF19 is linked to primary biliary cholangitis.